Lianchuan Bio Snags ￥115M in Series B Financing

According to VCBeat, recently, Hangzhou Lianchuan Biotechnology Co., Ltd. ("Lianchuan Bio"）announced the completion of a ￥115 million Series B financing, led by Hangzhou Heda Biomedical Venture Capital, with participation from Beijing Junchuan Capital, Hangzhou Taimeng Investment and the existing shareholders Sinowisdom Investment, Zheshang Venture Capital, Crestvalue Capital, etc. The funds raised will be used for the R&D of its platforms for gene capture and gene synthesis, as well as the technical transformation and marketing in the field of clinical genetic testing.

Founded in 2006, Lianchuan Bio is a biotechnology company focused on providing customized solutions and products of genetic testing for scientific research institutions, and enterprises in precision medicine.

In recent years, Lianchuan Bio has been devoted to dealing with the problems of controlling cost while ensuring accuracy and shortening cycle time by using genetic testing technology effectively. After years of hard work, the scientists of Lianchuan Bio developed VariantPro^TM one-step targeted capture technology of gene, which significantly improved the sensitivity of testing by introducing molecular tags while simplifying the capture process to one step, thus reducing the error of human operation to ensure the accuracy of the results.

Based on the autonomous platform of gene synthesis, the capture probe can be synthesized on a large scale and with high fidelity, which overcomes the problem of high threshold and high cost of synthesizing key raw materials in the development of gene testing kits, and offers the opportunity to realize whole-process genetic testing.

Lianchuan Bio will accelerate the process of self-development, so as to break the situation of strong dependence on imports and high cost in the gene-sequencing industry in China.

Founded in 2002, Sinowisdom Investment has more than 60 funds under management with AUM over 10 billion yuan. The company is focused on the investments in digital economy, electronic information, new energy, new materials and life sciences.

ZSVC has currently managed more than 30 VC/PE funds, NEEQ funds, private placement funds, mergers and acquisitions funds, with AUM of approximately 40 billion yuan.

ZSVC mainly invested in big health, big consumption, new economy, new manufacturing and other fields.